NEW YORK (GenomeWeb) – Novartis has filed a new drug application with the US Food and Drug Administration for its investigational drug alpelisib — an alpha-specific PI3 kinase inhibitor that shows promise for treating hormone receptor-positive, HER2-negative advanced breast cancers with PIK3CA mutations.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.